ABOS vs. IPHA, ELEV, OPT, CRDF, CMPX, KOD, IPSC, XFOR, OVID, and PSTX
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Innate Pharma (IPHA), Elevation Oncology (ELEV), Opthea (OPT), Cardiff Oncology (CRDF), Compass Therapeutics (CMPX), Kodiak Sciences (KOD), Century Therapeutics (IPSC), X4 Pharmaceuticals (XFOR), Ovid Therapeutics (OVID), and Poseida Therapeutics (PSTX). These companies are all part of the "medical" sector.
Acumen Pharmaceuticals (NASDAQ:ABOS) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.
Acumen Pharmaceuticals presently has a consensus target price of $12.25, suggesting a potential upside of 295.16%. Innate Pharma has a consensus target price of $9.75, suggesting a potential upside of 306.25%. Given Innate Pharma's higher possible upside, analysts clearly believe Innate Pharma is more favorable than Acumen Pharmaceuticals.
In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Acumen Pharmaceuticals and 1 mentions for Innate Pharma. Acumen Pharmaceuticals' average media sentiment score of 1.05 beat Innate Pharma's score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.
71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 7.5% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Innate Pharma received 20 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 64.29% of users gave Acumen Pharmaceuticals an outperform vote while only 54.29% of users gave Innate Pharma an outperform vote.
Innate Pharma has higher revenue and earnings than Acumen Pharmaceuticals.
Acumen Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
Innate Pharma's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.
Summary
Innate Pharma beats Acumen Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
